Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Morris, Roberta; 1 | Umeukeje, Gibreta; 1 | Bu, Kunb; 1 | Cheng, Fenga; c; *
Affiliations: [a] Department of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL, USA | [b] Department of Mathematics & Statistics, College of Art and Science, University of South Florida, Tampa, FL, USA | [c] Department of Biostatistics & Epidemiology, College of Public Health, University of South Florida, Tampa, FL, USA
Correspondence: [*] Correspondence to: Feng Cheng, PhD, Department of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, 12901 Bruce B Downs Blvd, MDC30, Tampa, FL 33612, USA. Tel.: +1 813 974 4288; E-mail: [email protected].
Note: [1] These authors contributed equally to this work.
Abstract: Background:Pneumonia is an inflammatory condition induced by infection of the lungs and is frequently a cause of morbidity and mortality among patients with Alzheimer’s disease (AD). Some studies have shown an association between acetylcholinesterase inhibitor use and elevated pneumonia risk. Objective:The purpose of this study was to perform a comparative analysis of the number of reported pneumonia cases in individuals prescribed rivastigmine relative to the number of reported cases by patients using other therapeutics including over-the-counter drugs and other AD therapeutics, as reported to the FDA Adverse Event Reporting System (FAERS) database. Methods:A disproportionality analysis was conducted to investigate the association between using rivastigmine and risk of pneumonia. Age, gender, dosage, temporality, and geographic distribution of reported cases were also assessed. Results:Patients prescribed rivastigmine were more likely to report pneumonia as an adverse event than many drugs except galantamine. Males were found to be 46% more likely than females to report pneumonia as an adverse event while likelihood of pneumonia diagnosis increases 3–5-fold in patients older than 65 years of age. Conclusion:The observed elevated frequency of aspiration pneumonia in patients prescribed rivastigmine may be due to an induced cholinergic crisis that is selective for the medulla oblongata, resulting in gastrointestinal distress, impaired swallowing, heightened salivation, and labored breathing. The observed elevated frequency of infectious pneumonia in patients prescribed rivastigmine may also be linked to overstimulation of neurons in the medulla oblongata and downstream suppression of localized inflammatory responses.
Keywords: Acetylcholine, acetylcholinesterase inhibitors, Alzheimer’s disease, aspiration pneumonia, medulla oblongata, rivastigmine, FAERS
DOI: 10.3233/JAD-210662
Journal: Journal of Alzheimer's Disease, vol. 83, no. 3, pp. 1061-1071, 2021
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]